You are here: Industry Insights > Sanofi

News List

Sanofi concludes acquisition of Principia Biopharma expresspharma
October 09, 2020
The Principia acquisition strengthens Sanofi’s core areas of autoimmune and allergic diseases.
EU to receive 300 million COVID-19 vaccine doses from Sanofi and GSK europeanpharmaceuticalreview
September 27, 2020
A contract for 300 doses of the investigational COVID-19 vaccine candidate has been signed by the European Commission (EC).
Sanofi and GSK sign Covid-19 vaccine supply deal with Canada pharmaceutical-technology
September 24, 2020
Sanofi and GlaxoSmithKline (GSK) have signed a deal with the Government of Canada to supply up to 72 million doses of adjuvanted Covid-19 vaccine candidate from next year.
Sanofi and GSK agree to supply Covid-19 vaccine doses to EU pharmaceutical-technology
September 22, 2020
Sanofi and GlaxoSmithKline (GSK) have signed an advanced purchase agreement with the European Commission (EC) to supply up to 300 million doses of their potential Covid-19 vaccine, following regulatory approval.
Three major deals contributed 74 per cent of deal value in August 2020 expresspharma
September 07, 2020
In August 2020, the healthcare industry reported 59 deals worth $35.4 billion as compared to the last 12-month average (August 2019 to July 2020) of 73 deals worth $10 billion.
Sanofi impacted by disrupted clinical trials and lagging vaccine development due to COVID-19: GlobalData expresspharma
September 07, 2020
Six of Sanofi’s clinical trials, which were being conducted in 31 countries, have been disrupted, which might impact the company's regulatory decisions.
Sanofi, GSK initiate Phase 1/2 clinical trial of COVID-19 vaccine candidate expresspharma
September 04, 2020
440 participants are being enrolled in the trial across 11 investigational sites in the US, companies expect first results in early December 2020.
Further clinical trials testing Kevzara as COVID-19 therapy to be halted europeanpharmaceuticalreview
September 03, 2020
After Kevzara (sarilumab) did not meet its primary or secondary endpoints in a Phase III trial, Sanofi and Regeneron have said they do not expect to conduct further studies on the drug against COVID-19.
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. worldpharmanews
September 02, 2020
Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg[1] in severely or critically ill[2] patients hospitalized with COVID-19 did not meet its primary endpoint and ...
Kevzara fails in PhIII COVID-19 trial pharmatimes
September 02, 2020
Sanofi and Regeneron's rheumatoid arthritis drug Kevzara (sarilumab) has failed to hit targets in a late-stage trial involving patients hospitalised with COVID-19, signalling the end of its development in this area.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page